Literature DB >> 23541998

Effects of cannabis use on event related potentials in subjects at ultra high risk for psychosis and healthy controls.

Mirjam J van Tricht1, Emma C Harmsen, Johannes H T M Koelman, Lo J Bour, Thérèse A van Amelsvoort, Don H Linszen, Lieuwe de Haan, Dorien H Nieman.   

Abstract

Cannabis use has consistently been associated with psychotic symptoms as well as cognitive impairments. Moreover, its use may provoke subclinical psychotic symptoms and is associated with neuropsychological dysfunctions in subjects at ultra high risk (UHR) for developing psychosis. However, to our knowledge, no data are yet available on the relationship between cannabis use, UHR symptoms and information processing as assessed with event related potentials (ERP) in UHR subjects. This cross-sectional study therefore aimed to investigate N100, N200, P200 and P300 ERP components in 48 UHR subjects (19 cannabis users; UHR+C) and 50 healthy controls (21 cannabis users; HC+C). Results showed smaller P300 amplitudes in HC+C and UHR subjects compared to HC-C. Moreover, HC+C showed prolonged P300 and N200 latencies compared to HC-C and UHR-C. No significant ERP differences were found between UHR+C and UHR-C. Regarding the relationship between information processing and psychopathology, we found associations between ERP components and severity of UHR symptoms, findings being most pronounced for N100 latencies and P300 amplitudes and severity of general psychopathology and positive symptoms. We conclude that UHR subjects and healthy cannabis users demonstrate similar P300 amplitude reductions compared to non-using control subjects. In addition, the interrelation of cannabis use with prolonged ERP latencies may signify reduced information processing speed associated with cannabis use. Finally, our findings cautiously support the hypothesis that the clinical phenomena of the UHR state may be associated with abnormalities in stimulus processing.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23541998     DOI: 10.1016/j.ijpsycho.2013.03.012

Source DB:  PubMed          Journal:  Int J Psychophysiol        ISSN: 0167-8760            Impact factor:   2.997


  5 in total

Review 1.  Cannabis use in individuals at clinical high-risk for psychosis: a comprehensive review.

Authors:  Megan S Farris; Mohammed K Shakeel; Jean Addington
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2019-12-03       Impact factor: 4.328

2.  The utility of P300 as a schizophrenia endophenotype and predictive biomarker: clinical and socio-demographic modulators in COGS-2.

Authors:  Bruce I Turetsky; Erich M Dress; David L Braff; Monica E Calkins; Michael F Green; Tiffany A Greenwood; Raquel E Gur; Ruben C Gur; Laura C Lazzeroni; Keith H Nuechterlein; Allen D Radant; Larry J Seidman; Larry J Siever; Jeremy M Silverman; Joyce Sprock; William S Stone; Catherine A Sugar; Neal R Swerdlow; Debby W Tsuang; Ming T Tsuang; Gregory Light
Journal:  Schizophr Res       Date:  2014-10-11       Impact factor: 4.939

3.  Cannabis use and symptom severity in individuals at ultra high risk for psychosis: a meta-analysis.

Authors:  R Carney; J Cotter; J Firth; T Bradshaw; A R Yung
Journal:  Acta Psychiatr Scand       Date:  2017-02-07       Impact factor: 6.392

4.  Are cannabis-using and non-using patients different groups? Towards understanding the neurobiology of cannabis use in psychotic disorders.

Authors:  Musa Basseer Sami; Sagnik Bhattacharyya
Journal:  J Psychopharmacol       Date:  2018-03-29       Impact factor: 4.153

Review 5.  Biomarkers and neuromodulation techniques in substance use disorders.

Authors:  Bettina Habelt; Mahnaz Arvaneh; Nadine Bernhardt; Ivan Minev
Journal:  Bioelectron Med       Date:  2020-02-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.